Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.34 -7.1%	$1.72	$0.87 ▼ $6.37	$255.05M	0.86	1.64 million shs	839,948 shs
CRON Cronos Group	$2.60 -0.2%	$2.13	$1.60 ▼ $2.77	$995.90M	1.01	3.17 million shs	5.35 million shs
VALN Valneva	$9.43 -19.0%	$7.48	$3.62 ▼ $12.25	$990.49M	1.77	87,673 shs	348,566 shs
VERV Verve Therapeutics	$11.13	$11.13	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	+12.00%	+43.18%	+103.23%	-52.54%
CRON Cronos Group	0.00%	+9.70%	+26.83%	+28.08%	+11.11%
VALN Valneva	0.00%	+0.95%	+51.56%	+88.35%	+50.00%
VERV Verve Therapeutics	0.00%	0.00%	-0.67%	+155.28%	+125.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.8716 of 5 stars	3.1	2.0	4.5	2.5	2.5	0.0
CRON Cronos Group	0.3929 of 5 stars	0.0	3.0	0.0	0.6	0.0	1.3
VALN Valneva	2.1763 of 5 stars	3.5	3.0	0.0	2.6	0.8	0.0
VERV Verve Therapeutics	2.9554 of 5 stars	4.2	4.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	78.06% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
VALN Valneva	3.00	Buy	$16.00	69.67% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside

Current Analyst Ratings Breakdown

Latest ALEC, CRON, VERV, and VALN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/19/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	2.36	N/A	N/A	$1.29 per share	1.81
CRON Cronos Group	$117.61M	8.45	N/A	N/A	$2.90 per share	0.89
VALN Valneva	$183.52M	4.37	$0.08 per share	119.13	$2.41 per share	3.91
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	11/5/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.05	51.90	86.50	N/A	14.19%	-3.78%	-3.62%	11/11/2025 (Estimated)
VALN Valneva	-$13.25M	-$0.98	N/A	N/A	N/A	-33.87%	-34.78%	-13.43%	11/6/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	N/A

Latest ALEC, CRON, VERV, and VALN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	$54.84 million
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
CRON Cronos Group	N/A	24.65	23.53
VALN Valneva	0.66	2.27	1.77
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
CRON Cronos Group	8.71%
VALN Valneva	11.39%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
CRON Cronos Group	6.90%
VALN Valneva	14.91%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
CRON Cronos Group	450	383.04 million	356.61 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable

ALEC, CRON, VERV, and VALN Headlines

Recent News About These Companies

Analysts Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $14.57

August 25 at 2:45 AM | americanbankingnews.com

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

August 9, 2025 | theglobeandmail.com

Verve Therapeutics Announces Merger and Nasdaq Delisting

August 3, 2025 | theglobeandmail.com

GSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

August 2, 2025 | marketbeat.com

Gene Therapy Companies Set Sights on Cardiovascular Disease

August 1, 2025 | genengnews.comG

Y Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 31, 2025 | marketbeat.com

Cwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

July 29, 2025 | msn.com

Eli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 26, 2025 | finanznachrichten.de

Verve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street Zen

July 26, 2025 | marketbeat.com

Eli Lilly completes acquisition of Verve Therapeutics

July 25, 2025 | msn.com

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25, 2025 | prnewswire.com

Lilly and Verve announce expiration of Verve tender offer

July 24, 2025 | prnewswire.com

Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly

July 24, 2025 | msn.com

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

July 24, 2025 | finance.yahoo.com

3 Bullish Biotech Stocks With Explosive Growth Trends

...

July 21, 2025 | marketbeat.com

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16, 2025 | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15, 2025 | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14, 2025 | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALEC, CRON, VERV, and VALN Company Descriptions

Alector NASDAQ:ALEC

$2.34 -0.18 (-7.14%)

Closing price 04:00 PM Eastern

Extended Trading

$2.32 -0.02 (-1.07%)

As of 07:52 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Cronos Group NASDAQ:CRON

$2.60 -0.01 (-0.19%)

Closing price 03:59 PM Eastern

Extended Trading

$2.60 +0.01 (+0.39%)

As of 07:58 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Valneva NASDAQ:VALN

$9.43 -2.21 (-18.99%)

Closing price 04:00 PM Eastern

Extended Trading

$9.26 -0.17 (-1.80%)

As of 07:53 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)

As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time